Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?

Breast Cancer. 2016 Jan;23(1):1-3. doi: 10.1007/s12282-015-0657-0.

Authors

Shigehira Saji¹, Reiko Kimura-Tsuchiya², Eisaku Sasaki²

Affiliations

¹ Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. ssaji@fmu.ac.jp.
² Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.

PMID: 26534859
DOI: 10.1007/s12282-015-0657-0

No abstract available

Publication types

Introductory Journal Article

MeSH terms

Aminopyridines / therapeutic use
Antineoplastic Agents / therapeutic use
Breast Neoplasms / diagnosis*
Breast Neoplasms / drug therapy
Breast Neoplasms / genetics
Breast Neoplasms / metabolism
Carcinoma / diagnosis*
Carcinoma / drug therapy
Carcinoma / genetics
Carcinoma / metabolism
Cyclin-Dependent Kinase 4 / genetics
Cyclin-Dependent Kinase 4 / metabolism
Cyclin-Dependent Kinase 6 / genetics
Cyclin-Dependent Kinase 6 / metabolism
Estradiol / analogs & derivatives
Estradiol / therapeutic use
Everolimus / therapeutic use
Female
Fulvestrant
Humans
Molecular Targeted Therapy
Pathology, Molecular
Piperazines / therapeutic use
Precision Medicine*
Purines / therapeutic use
Pyridines / therapeutic use
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism
Receptors, Estrogen / genetics
Receptors, Estrogen / metabolism
TOR Serine-Threonine Kinases / genetics
TOR Serine-Threonine Kinases / metabolism
Tamoxifen / therapeutic use
Trastuzumab / therapeutic use

Substances

Aminopyridines
Antineoplastic Agents
Piperazines
Purines
Pyridines
Receptors, Estrogen
Tamoxifen
Fulvestrant
Estradiol
Everolimus
ERBB2 protein, human
Receptor, ErbB-2
TOR Serine-Threonine Kinases
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
palbociclib
Trastuzumab
ribociclib